<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03816852</url>
  </required_header>
  <id_info>
    <org_study_id>SCLnow-HNRM-01</org_study_id>
    <nct_id>NCT03816852</nct_id>
  </id_info>
  <brief_title>The Safety and Efficiency Study of Mesenchymal Stem Cell in Premature Ovarian Insufficiency</brief_title>
  <official_title>Clinical Study on the Safety and Effectiveness of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sclnow Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sclnow Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety of human umbilical cord mesenchymal stem cells (hucMSCs) in POI&#xD;
      treatment; Evaluate the effective hucMSCs in POI treatment. Compare different infusion mode,&#xD;
      meanwhile compare with hormone replacement therapy (HRT) withdrawal, so that assessing the&#xD;
      stem cell therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premature ovarian insufficiency (POI) or premature ovarian failure (POF), is the loss of&#xD;
      function of the ovaries before age 40, which has the features of menstrual disorder with high&#xD;
      gonadotropic hormone and low estrogen. The morbidity of POI is about 0.1% among woman before&#xD;
      40 years, 10-28% among woman with primary amenorrhea, and 4-18% among woman with secondary&#xD;
      amenorrhea. Recent years research shows different sources of stem cell could be used to POI,&#xD;
      and with effective results.&#xD;
&#xD;
      Above all, this experiment designed to as a single center, random, and control experiment.&#xD;
      treat POI patients wit human umbilical cord mesenchymal stem cells (MSCs). After regular&#xD;
      follow-up and analysis, assessing the safety and effective of MSCs in POI treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Others&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Menstrual changes</measure>
    <time_frame>270 days</time_frame>
    <description>Observe the change of patients with irregular menstrual cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kupperman score</measure>
    <time_frame>270 days</time_frame>
    <description>Mild: &lt;14; moderate: 14-26; serious: &gt;26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hormone level</measure>
    <time_frame>270 days</time_frame>
    <description>Test the level change of Follicle-Stimulating Hormone (FSH), estrogen (E2), and Anti Mullerian Hormone (AMH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicular development</measure>
    <time_frame>270 days</time_frame>
    <description>Observe the size of ovarian follicles in each cycle.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion with hucMSCs, 9*10^7 cells, 30ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion with hucMSCs, 6*10^7 cells, 30ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion with hucMSCs, 3*10^7 cells, 30ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hucMSCs</intervention_name>
    <description>Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_label>Medium dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet diagnostic criteria of European Society of Human Reproduction and Embryology&#xD;
&#xD;
          -  No hormonotherapy and chinese traditional medicine within 3 months;&#xD;
&#xD;
          -  Understand and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with congenital adrenocortical hyperplasia;&#xD;
&#xD;
          -  Patient with Cushing syndrome;&#xD;
&#xD;
          -  Patient with Thyroid dysfunction;&#xD;
&#xD;
          -  Patient with hyperprolactinemia;&#xD;
&#xD;
          -  Patient with pituitary amenorrhea or hypothalamic amenorrhea;&#xD;
&#xD;
          -  Patient with HIV, hepatitis;&#xD;
&#xD;
          -  Gene defect (eg. Turner syndrome, fragile X syndrome)&#xD;
&#xD;
          -  Serious drug allergy history;&#xD;
&#xD;
          -  Suffering from thrombophlebitis, thromboembolism including venous thrombosis and&#xD;
             arterial thrombosis;&#xD;
&#xD;
          -  History of treatment of ovarian cysts or ovarian surgery&#xD;
&#xD;
          -  With high tumor marker;&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Receive other treatments that may affect the efficacy and safety of stem cells;&#xD;
&#xD;
          -  Do not understand or without sign informed consent;&#xD;
&#xD;
          -  The attending physician believes that it is not suitable for participating in this&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guangzhi Liu, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Henan Provincial People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Premature Ovarian Failure</keyword>
  <keyword>Premature Ovarian Insufficiency</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

